Enantia is a company devoted to chemical research and development, medicinal chemistry support and crystal engineering, with a strong focus on asymmetric chemistry and co-crystallisation technologies.
The company was founded in 2003 to combine the expertise of leading university academics with a strong client oriented focus and professional management. Due to the ample industrial experience accumulated, Enantia is seen by its clients as the partner of choice to translate creative chemistry into robust processes running at industrial scale.
Mainly located at Barcelona’s Science Park, at the heart of Barcelona’s Pharma and Biotech cluster, it has five fully equipped laboratories and access to state of the art facilities, excellent installations and instrumentation: HPLC and HPLC-MS (chiral/achiral), GC (chiral/achiral), preparative HPLC (chiral/achiral), automated chromatography, Gel Permeation Chromatography, NMR (from 400 to 800 MHz), Mass Spectra, FT-IR and UV chemistry, kilo-lab, X-Ray Diffraction and spray dryer.
Enantia has a vast experience in general organic synthesis and in process development, especially in the fields of asymmetric synthesis, enantioselective catalysis and metal-mediated coupling reactions. This expertise is applied to a wide scope of project types serving a variety of markets.
Enantia can accompany the client in all stages of drug discovery and drug development:
The company has experience in a wide range of chemical transformations, and holds a particular know-how in asymmetric reactions such as Sharpless enantioselective epoxidation and dihydroxylation, enantioselective hydrogenations, enantioselective alkylations and arylations and also expertise in ring closing metathesis, Suzuki and Negishi couplings, and innovative Swern and Corey Kim oxidations.
Co-crystals (crystalline materials composed of two or more molecules in the same crystal lattice in which the components are in a neutral state and interact via non-ionic interactions) emerge as a powerful tool for the Pharmaceutical and Generic Industry.
On one hand, as a different solid form, they can modify the physicochemical properties of organic molecules including Active Pharmaceutical Ingredients (APIs), intermediates and other synthetic products.
On the other hand, the specificity of co-crystal formation makes them a very powerful tool to be applied in process chemistry. They can be used to resolve racemic mixtures and to improve purification processes. Moreover, co-crystallisation is applicable to non-ionisable molecules where salt formation is not possible.
Enantia has a track record in the field of co-crystal discovery and development. Its dedicated team has its own particular approach to co-crystal screening, offering a combination of rational design and a powerful set of synthetic and analytical techniques.
Through Enantia’s differential technologies, the company offers a 360 degree solution to critical issues of its clients providing them with innovative tools to achieve objective value.
As a result of Enantia’s expertise in organic synthesis and co-crystallisation technologies the company has its own lines of research developing chemical and solid state technologies for future generics to license to third parties. With an average of 4 patent filings per year, the company has several examples of generics drugs in the market being produced by the technology developed by the company.